Priming the proteasome to protect against aging and Alzheimer's disease
Priming the proteasome to protect against aging and Alzheimer's disease
批准号:
10448146
负责人:
XUEJUN WANG
金额:
$162.59万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2025-06-30
关键词:
26S proteasomeAdenylate CyclaseAffectAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease therapeuticAnimal DiseasesAttentionBrainBrain DiseasesCause of DeathCessation of lifeCharacteristicsClosure by clampCognitiveCyclic AMPCyclic AMP-Dependent Protein KinasesDataDementiaDeteriorationDevelopmentDiseaseDisease ProgressionExhibitsFinancial HardshipForskolinFunctional disorderGenesGeneticHeartHeart DiseasesHeart failureHippocampus (Brain)ImpairmentKnock-inKnock-in MouseLearningLinkLongevityMediatingMemory LossMemory impairmentMethodsModelingMolecularMusMutant Strains MiceMutateMutationMyocardial dysfunctionNational Institute on AgingNeurofibrillary TanglesNeuronsOrganPathogenesisPathologyPeripheralPersonsPharmaceutical PreparationsPharmacologyPhosphorylationPhysiologicalPilot ProjectsPlayProcessProtein KinaseProteinsQuality ControlReporterReportingResearchRisk FactorsRoleRolipramSenile PlaquesSerineSignal TransductionSymptomsSystemTestingTherapeuticTimeUbiquitinUbiquitin Like ProteinsUnited StatesWorkaging brainbrain cellbrain dysfunctionclinically translatablecognitive functiondefined contributiondesigneffective therapyfamilial Alzheimer diseasehuman old age (65+)inhibitorinnovationinsightmiddle agemimicrymisfolded proteinmouse modelmulticatalytic endopeptidase complexneurobiological mechanismoverexpressionparticlephosphodiesterase IVpreventprotein activationprotein degradationproteostasisresponsesuccesstherapeutic targettherapeutically effective
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Alzheimer’s disease (AD) is the most common cause of dementia that affects million people and poses a
serious financial burden to the nation. However, to develop effective therapeutics for AD has been a challenge.
To date, no effective treatment is available to either prevent the disease or halt its progression. A major hurdle
for this is the lack of reliable therapeutic targets for the disease. AD is associated with accumulation of
misfolded proteins including senile (Aβ) plaques and neurofibrillary tangles. It remains unclear how these
protein accumulations occur and what roles they play in the pathogenesis of AD. Additionally, AD is a
multifactorial disease exhibiting symptoms both in the brain and heart. However, the temporal relationship
between the peripheral symptoms to AD pathogenesis remains unknown. In response to the NOT-AG-18-051
from the National Institute on Aging, we propose to study the role of a key phosphoregulation of the
proteasome in aging and AD. Specifically, we will determine whether changes in proteasome functionality,
through increase or decrease of Rpn6 phosphorylation at the serine-14 residue (Ser14-Rpn6 phosphorylation),
alter aging process and AD pathogenesis in both the brain and heart. Two unique mouse knock-in models,
phosphorylation mimicry and phosphorylation blockade at Ser14-Rpn6, will be studied at baseline and when
crossed with an AD mouse model to generate the phosphorylation mimicry-AD and phosphorylation blockade-
AD mice. Furthermore, the contribution of proteasome activation by PKA to the therapeutic benefits to the brain
and heart of AD animals exerted by a pharmacological strategy that can augment cAMP/PKA signaling and
increase Ser14-Rpn6 phosphorylation and proteasome activities in both the brain and heart will be determined.
This work will lead to significant mechanistic insight into a key phosphoregulation of the proteasome in
protection against aging and AD. Success of this work can also advance the mechanistic understanding of a
clinically translatable therapeutic strategy for the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cardiac Pathophysiology of Proteasome Phosphoregulation
-
批准号:10224336
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2020
-
负责人:XUEJUN WANG
-
依托单位:
Cardiac Pathophysiology of Proteasome Phosphoregulation
-
批准号:10033517
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2020
-
负责人:XUEJUN WANG
-
依托单位:
Cardiac Pathophysiology of Proteasome Phosphoregulation
-
批准号:10627948
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2020
-
负责人:XUEJUN WANG
-
依托单位:
Cardiac Pathophysiology of Proteasome Phosphoregulation
-
批准号:10435491
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2020
-
负责人:XUEJUN WANG
-
依托单位:
Molecular Pathogenesis of Protein Surplus Cardiomyopathy
-
批准号:7822353
-
项目类别:
-
资助金额:$1.66万
-
财政年份:2009
-
负责人:XUEJUN WANG
-
依托单位:
SD COBRE: UBIQUITIN-PROTEASOME IN CARDIAC REMODELING AND FAILURE
-
批准号:7720647
-
项目类别:
-
资助金额:$16.18万
-
财政年份:2008
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 SIgnalosome in the Heart
-
批准号:8800567
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 Signalosome in the Heart
-
批准号:7433756
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 Signalosome in the Heart
-
批准号:7631261
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 SIgnalosome in the Heart
-
批准号:8457106
-
项目类别:
-
资助金额:$34.48万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 Signalosome in the Heart
-
批准号:7136917
-
项目类别:
-
资助金额:$37.86万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 Signalosome in the Heart
-
批准号:7846720
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
SD COBRE: UBIQUITIN-PROTEASOME IN CARDIAC REMODELING AND FAILURE
-
批准号:7381825
-
项目类别:
-
资助金额:$14.68万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 SIgnalosome in the Heart
-
批准号:8628863
-
项目类别:
-
资助金额:$35.53万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 Signalosome in the Heart
-
批准号:7248729
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
The COP9 SIgnalosome in the Heart
-
批准号:8310341
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2006
-
负责人:XUEJUN WANG
-
依托单位:
SD COBRE: UBIQUITIN-PROTEASOME IN CARDIAC REMODELING AND FAILURE
-
批准号:7171045
-
项目类别:
-
资助金额:$15.07万
-
财政年份:2005
-
负责人:XUEJUN WANG
-
依托单位:
SD COBRE: MOLECULAR BIOLOGY CORE
-
批准号:7171044
-
项目类别:
-
资助金额:$10.73万
-
财政年份:2005
-
负责人:XUEJUN WANG
-
依托单位:
CORE--SD COBRE: MOLECULAR BIOLOGY
-
批准号:6981730
-
项目类别:
-
资助金额:$10.35万
-
财政年份:2004
-
负责人:XUEJUN WANG
-
依托单位:
SD COBRE: UBIQUITIN-PROTEASOME IN CARDIAC REMODELING AND FAILURE
-
批准号:6981731
-
项目类别:
-
资助金额:$27.76万
-
财政年份:2004
-
负责人:XUEJUN WANG
-
依托单位:
海外基金